Market Intelligence, Clinical Progress, and High-Purity Reagents for Metastasis, Fibrosis, and Oncology Development.
Note: S100A4 (Fibroblast-Specific Protein 1) is distinct from the ferroptosis regulator FSP1 (AIFM2); this portfolio addresses the S100A4 metastasis/fibrosis target.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for S100A4 (FSP1) drug discovery. Select your assay components below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Holo-form) | S100A4 (FSP1) Recombinant Protein - Ca2+ Loaded. High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, Theoretical MW confirmed. | View S100A4 Products |
| Antigen (Apo-form) | S100A4 Recombinant Protein - Calcium-free (EDTA-treated). Conformationally distinct for mechanism studies. SEC validated. | View S100A4 Products |
| Mutant Panel | EF-hand Mutants (E67A, E94A). Calcium-binding deficient; critical for specificity controls in screening. | View S100A4 Products |
| Benchmark Ab | Anti-S100A4 Neutralizing Antibody (Recombinant). Sequence of lead therapeutic clone; positive control for functional assays. | View S100A4 Products |
| Gene Delivery | S100A4 ORF Lentivirus Particles. Full-length ORF for stable cell line generation. Puromycin selectable. | View S100A4 Products |
| Validator | S100A4 siRNA Set. For knockdown verification and specificity checks. | View S100A4 Products |
| Related Target A | RAGE (AGER). Primary extracellular receptor for secreted S100A4 mediating TME signaling. | View RAGE Products |
| Related Target B | TLR4. Alternative pro-inflammatory receptor pathway for S100 proteins. | View TLR4 Products |
| Related Target C | S100A8 (Calgranulin A). Pro-inflammatory partner; heterodimerizes with S100A9. | View S100A8 Products |
| Related Target D | S100A9 (Calgranulin B). Key partner in calprotectin complex; regulates myeloid cell migration. | View S100A9 Products |
Critical Assay Challenges & TarMart Technical Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent conformational switching (Holo vs Apo) | Holo (Ca2+-bound) and Apo-forms available; defined EF-hand occupancy status for mechanism-based SPR/BLI. |
| Oligomerization state interference | Monomeric fractions validated by SEC; theoretical MW confirmed by Mass Spec to exclude aggregates. |
| Extracellular vs Intracellular targeting | Native signal peptide sequence preserved; available with or without secretion tag for compartment-specific assays. |
| Cross-species translation (Human/Mouse/Cyno) | Ortholog proteins with >92% sequence homology; conserved EF-hand domains verified. |
| S100 family cross-reactivity | High-precision homolog panel (S100A6, S100B, S100A8/A9) strictly verified by mass spec for selectivity counter-screening. |
| Lack of controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| False positives in cell assays | Validated siRNA included for precise intracellular knockdown specificity checks. |
Live S100A4 R&D Tracker
Real-time intelligence on global development status:
- ➤ View Active Clinical Trials (Anti-fibrosis and anti-metastasis candidates)
- ➤ Latest Inhibitor Research (Small molecule EF-hand binders)
- ➤ Recent Patent Filings (Antibody and small molecule compositions)
Global Clinical Landscape & Future Outlook
The S100A4 target is experiencing renewed interest as a stromal-directed therapy node. While first-generation approaches focused on generic S100 family inhibition, current R&D emphasizes selective S100A4 blockade to disrupt cancer-associated fibroblast (CAF) activation without compromising immune surveillance. The modality landscape is shifting from pan-S100 inhibitors toward epitope-specific antibodies and allosteric EF-hand blockers.
Key inflection points: (1) Combination trials with checkpoint inhibitors in desmoplastic tumors; (2) Cardiac fibrosis applications post-MI; (3) Distinction between secreted (paracrine) and intracellular (motility) S100A4 pools requiring orthogonal assay strategies. Major players are focusing on targeted monoclonal antibodies that neutralize the extracellular fraction of S100A4, and pairing S100A4 blockade with immune checkpoint inhibitors to reverse immune exclusion in solid tumors, or utilizing it as a core target in Idiopathic Pulmonary Fibrosis (IPF).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (EF-hand binder) | Academic consortia, Fibrosis-focused biotechs | IPF, Metastatic Breast Cancer | Mutant vs WT binding assays (Need E67A/E94A controls) |
| Neutralizing mAb (Secreted S100A4) | Preclinical antibody firms, Biotech | Pancreatic Cancer (CAF-rich), Solid Tumors | Native conformation binding (Need correctly folded Holo-protein, <1 EU/µg endotoxin) |
| Targeted Degradation (PROTAC) | Emerging platform companies | Fibrotic Disease | Intracellular stability assays (Need high-expression lentivirus) |
| Anti-metastatic Peptide | University spin-offs | Colon Cancer | Myosin IIA competition assays (Need pure monomeric protein) |
| RNAi / Gene Therapy | Early preclinical innovators | Liver Fibrosis, Advanced Melanoma | Knockdown validation (Need sequence-verified siRNA) |
| Bispecific / Combination | Large Pharma pipeline synergies | Refractory Solid Tumors | Pathway cross-talk analysis (Need RAGE/TLR4 related target proteins) |